Eupraxia Pharmaceuticals Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
49
- Stock Symbol
-
EPRX
- Investments
-
2
- Share Price
-
$6.13
- (As of Thursday Closing)
Eupraxia Pharmaceuticals General Information
Description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Contact Information
Website
www.eupraxiapharma.comCorporate Office
- 2198 Yukon Street
- Vancouver, British Columbia V5Y 3P1
- Canada
Corporate Office
- 2198 Yukon Street
- Vancouver, British Columbia V5Y 3P1
- Canada
Eupraxia Pharmaceuticals Timeline
Eupraxia Pharmaceuticals Stock Performance
As of 19-Nov-2026, Eupraxia Pharmaceuticals’s stock price is $6.13. Its current market cap is $412M with 67.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.13 | $6.19 | $5.61 - $9.29 | $412M | 67.3M | 91.2K | -$1.07 |
Eupraxia Pharmaceuticals Financials Summary
As of 30-Sep-2026, Eupraxia Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 500,717 | 322,011 | 102,423 | 95,691 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (62,943) | (39,761) | (26,127) | (28,467) |
| Net Income | (59,093) | (38,576) | (25,503) | (28,221) |
| Total Assets | 134,563 | 86,150 | 34,942 | 20,266 |
| Total Debt | 3,422 | 154 | 72 | 10,452 |
Eupraxia Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eupraxia Pharmaceuticals Comparisons
Industry
Financing
Details
Eupraxia Pharmaceuticals Competitors (47)
One of Eupraxia Pharmaceuticals’s 47 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Aurinia Pharmaceuticals | Corporation | Edmonton, Canada | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Arbutus Biopharma | Corporation | Warminster, PA |
Eupraxia Pharmaceuticals Patents
Eupraxia Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024310803-A1 | Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof | Pending | 26-Jun-2023 | ||
| EP-4731193-A1 | Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof | Pending | 26-Jun-2023 | ||
| US-20240424000-A1 | Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof | Pending | 26-Jun-2023 | ||
| WO-2025006497-A1 | Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof | Inactive | 26-Jun-2023 | ||
| AU-2023356957-A1 | Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract | Pending | 04-Oct-2022 | A61K9/0019 |
Eupraxia Pharmaceuticals Signals
Eupraxia Pharmaceuticals Acquisitions (2)
Eupraxia Pharmaceuticals’s most recent deal was a Merger/Acquisition with EpiPharma Therapeutics. The deal was made on 01-Jan-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EpiPharma Therapeutics | 01-Jan-2023 | Merger/Acquisition | Drug Discovery | ||
| AMDM Holdings | 31-Jan-2021 | Merger/Acquisition | Other Commercial Products |
Eupraxia Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Eupraxia Pharmaceuticals FAQs
-
When was Eupraxia Pharmaceuticals founded?
Eupraxia Pharmaceuticals was founded in 2011.
-
Where is Eupraxia Pharmaceuticals headquartered?
Eupraxia Pharmaceuticals is headquartered in Vancouver, Canada.
-
What is the size of Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals has 49 total employees.
-
What industry is Eupraxia Pharmaceuticals in?
Eupraxia Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Eupraxia Pharmaceuticals a private or public company?
Eupraxia Pharmaceuticals is a Public company.
-
What is Eupraxia Pharmaceuticals’s stock symbol?
The ticker symbol for Eupraxia Pharmaceuticals is EPRX.
-
What is the current stock price of Eupraxia Pharmaceuticals?
As of 19-Nov-2026 the stock price of Eupraxia Pharmaceuticals is $6.13.
-
What is the current market cap of Eupraxia Pharmaceuticals?
The current market capitalization of Eupraxia Pharmaceuticals is $412M.
-
Who are Eupraxia Pharmaceuticals’s competitors?
Protagonist Therapeutics, Aurinia Pharmaceuticals, Zymeworks, Aclaris Therapeutics, and Arbutus Biopharma are some of the 47 competitors of Eupraxia Pharmaceuticals.
-
What is Eupraxia Pharmaceuticals’s annual earnings per share (EPS)?
Eupraxia Pharmaceuticals’s EPS for 12 months was -$1.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process